This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Mimpara. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mimpara.

For practical information about using Mimpara, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 29/03/2023

Authorisation details

Product details
Agency product number
Active substance
cinacalcet hydrochloride
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Hypercalcemia
  • Parathyroid Neoplasms
  • Hyperparathyroidism
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Amgen Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Minervum 7061
NL-4817 ZK Breda
The Netherlands

Product information

29/12/2022 Mimpara - EMEA/H/C/000570 - N/0073

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Secondary hyperparathyroidism


Treatment of secondary hyperparathyroidism (HPT) in adult patients with end stage renal disease (ESRD) on maintenance dialysis therapy.

Paediatric population

Treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.

Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate.

Parathyroid carcinoma and primary hyperparathyroidism in adults.

Reduction of hypercalcaemia in adult patients with:

  • parathyroid carcinoma;
  • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating